| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 43 | 2022 | 2162 | 2.860 |
Why?
|
| Tissue Plasminogen Activator | 21 | 2018 | 296 | 2.350 |
Why?
|
| Fibrinolytic Agents | 20 | 2018 | 377 | 2.230 |
Why?
|
| Endovascular Procedures | 25 | 2019 | 366 | 1.970 |
Why?
|
| Research Design | 11 | 2022 | 729 | 1.880 |
Why?
|
| Brain Ischemia | 19 | 2022 | 665 | 1.810 |
Why?
|
| Brain Injuries, Traumatic | 9 | 2022 | 105 | 1.770 |
Why?
|
| Thrombolytic Therapy | 10 | 2017 | 233 | 1.120 |
Why?
|
| Progesterone | 8 | 2021 | 115 | 1.050 |
Why?
|
| Data Interpretation, Statistical | 3 | 2015 | 329 | 0.950 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 26 | 0.940 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2021 | 929 | 0.900 |
Why?
|
| Deferoxamine | 6 | 2022 | 45 | 0.830 |
Why?
|
| Glasgow Outcome Scale | 3 | 2020 | 15 | 0.820 |
Why?
|
| Cerebral Hemorrhage | 7 | 2022 | 198 | 0.760 |
Why?
|
| Infarction, Middle Cerebral Artery | 7 | 2019 | 105 | 0.740 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 253 | 0.700 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2022 | 1745 | 0.690 |
Why?
|
| Medical Futility | 4 | 2022 | 31 | 0.680 |
Why?
|
| Treatment Outcome | 36 | 2022 | 7028 | 0.680 |
Why?
|
| Thrombectomy | 6 | 2021 | 238 | 0.640 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2021 | 58 | 0.630 |
Why?
|
| Reperfusion | 6 | 2016 | 78 | 0.630 |
Why?
|
| Carotid Artery, Internal | 5 | 2020 | 85 | 0.620 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 848 | 0.610 |
Why?
|
| Aspirin | 2 | 2018 | 295 | 0.590 |
Why?
|
| Random Allocation | 2 | 2015 | 442 | 0.580 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2019 | 373 | 0.570 |
Why?
|
| Ischemia | 1 | 2018 | 229 | 0.560 |
Why?
|
| Humans | 80 | 2022 | 68549 | 0.560 |
Why?
|
| Cerebral Revascularization | 5 | 2014 | 45 | 0.530 |
Why?
|
| Cerebral Angiography | 12 | 2018 | 151 | 0.520 |
Why?
|
| Aged | 41 | 2021 | 14842 | 0.510 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2014 | 84 | 0.490 |
Why?
|
| Emergencies | 1 | 2015 | 107 | 0.490 |
Why?
|
| Double-Blind Method | 11 | 2022 | 1738 | 0.460 |
Why?
|
| Time-to-Treatment | 6 | 2019 | 117 | 0.460 |
Why?
|
| Severity of Illness Index | 10 | 2022 | 1851 | 0.450 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2022 | 109 | 0.430 |
Why?
|
| Middle Aged | 44 | 2021 | 21119 | 0.430 |
Why?
|
| Male | 55 | 2021 | 37283 | 0.430 |
Why?
|
| Female | 55 | 2021 | 38021 | 0.420 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2012 | 13 | 0.420 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2012 | 10 | 0.420 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 4843 | 0.420 |
Why?
|
| Collateral Circulation | 3 | 2015 | 34 | 0.380 |
Why?
|
| Leukoencephalopathies | 2 | 2021 | 13 | 0.370 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 2 | 2021 | 15 | 0.360 |
Why?
|
| Spectrin | 2 | 2021 | 17 | 0.360 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2021 | 24 | 0.360 |
Why?
|
| Brain Injuries | 3 | 2022 | 268 | 0.360 |
Why?
|
| Perfusion Imaging | 6 | 2020 | 27 | 0.360 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2021 | 92 | 0.350 |
Why?
|
| Patient Selection | 3 | 2021 | 592 | 0.340 |
Why?
|
| Mechanical Thrombolysis | 3 | 2019 | 29 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2021 | 2324 | 0.330 |
Why?
|
| Cerebrovascular Disorders | 2 | 2019 | 182 | 0.310 |
Why?
|
| Disease Progression | 3 | 2021 | 1037 | 0.310 |
Why?
|
| Bias | 2 | 2021 | 148 | 0.300 |
Why?
|
| Arterial Occlusive Diseases | 4 | 2016 | 134 | 0.300 |
Why?
|
| Young Adult | 18 | 2021 | 5710 | 0.280 |
Why?
|
| Prospective Studies | 12 | 2021 | 3703 | 0.270 |
Why?
|
| Clinical Decision-Making | 2 | 2017 | 109 | 0.270 |
Why?
|
| Adult | 29 | 2021 | 21379 | 0.260 |
Why?
|
| Intracranial Pressure | 2 | 2022 | 58 | 0.250 |
Why?
|
| Intracranial Thrombosis | 2 | 2014 | 14 | 0.250 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 225 | 0.250 |
Why?
|
| Time Factors | 13 | 2022 | 4655 | 0.250 |
Why?
|
| Intracranial Embolism | 2 | 2014 | 25 | 0.240 |
Why?
|
| Anesthesia, General | 2 | 2015 | 86 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 191 | 0.230 |
Why?
|
| Acute Disease | 3 | 2022 | 658 | 0.230 |
Why?
|
| Administration, Intravenous | 3 | 2018 | 89 | 0.220 |
Why?
|
| Bayes Theorem | 2 | 2022 | 307 | 0.220 |
Why?
|
| Disease Management | 2 | 2015 | 248 | 0.220 |
Why?
|
| Middle Cerebral Artery | 2 | 2020 | 57 | 0.210 |
Why?
|
| Combined Modality Therapy | 5 | 2018 | 951 | 0.210 |
Why?
|
| Algorithms | 4 | 2015 | 1195 | 0.210 |
Why?
|
| Infusions, Intravenous | 6 | 2021 | 334 | 0.200 |
Why?
|
| Cerebral Infarction | 2 | 2019 | 103 | 0.200 |
Why?
|
| Hematoma | 1 | 2021 | 47 | 0.200 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2020 | 134 | 0.200 |
Why?
|
| Robotic Surgical Procedures | 1 | 2022 | 49 | 0.200 |
Why?
|
| United States | 9 | 2022 | 7338 | 0.190 |
Why?
|
| Brain Hemorrhage, Traumatic | 1 | 2021 | 2 | 0.190 |
Why?
|
| Intubation, Intratracheal | 2 | 2018 | 99 | 0.180 |
Why?
|
| Therapeutic Equipoise | 1 | 2019 | 3 | 0.180 |
Why?
|
| Neurologists | 1 | 2019 | 15 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 689 | 0.170 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2019 | 7 | 0.170 |
Why?
|
| Prognosis | 6 | 2021 | 2093 | 0.170 |
Why?
|
| Iron Chelating Agents | 1 | 2019 | 31 | 0.170 |
Why?
|
| Diabetes Complications | 2 | 2018 | 249 | 0.170 |
Why?
|
| Carotid Stenosis | 2 | 2018 | 163 | 0.170 |
Why?
|
| Goals | 1 | 2019 | 65 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 2 | 2022 | 296 | 0.160 |
Why?
|
| Angioplasty | 1 | 2019 | 118 | 0.160 |
Why?
|
| Placebo Effect | 1 | 2018 | 20 | 0.160 |
Why?
|
| White Matter | 1 | 2021 | 174 | 0.160 |
Why?
|
| Carotid Artery Diseases | 2 | 2015 | 83 | 0.150 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 65 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 212 | 0.150 |
Why?
|
| Computer Simulation | 3 | 2016 | 706 | 0.150 |
Why?
|
| Adolescent | 11 | 2021 | 8904 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 2222 | 0.140 |
Why?
|
| Logistic Models | 3 | 2017 | 1419 | 0.140 |
Why?
|
| Albumins | 1 | 2016 | 72 | 0.140 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 317 | 0.140 |
Why?
|
| Administration, Oral | 2 | 2018 | 411 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 62 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 3256 | 0.130 |
Why?
|
| Biomarkers | 3 | 2021 | 1593 | 0.130 |
Why?
|
| Cocaine-Related Disorders | 2 | 2013 | 504 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 16 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 497 | 0.130 |
Why?
|
| Single-Blind Method | 3 | 2021 | 249 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1465 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 503 | 0.120 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2014 | 28 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2014 | 106 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 186 | 0.120 |
Why?
|
| Probability | 1 | 2014 | 244 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2017 | 346 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 521 | 0.120 |
Why?
|
| Dystonia | 1 | 2014 | 18 | 0.120 |
Why?
|
| Drug Interactions | 2 | 2012 | 289 | 0.120 |
Why?
|
| Siderophores | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 938 | 0.110 |
Why?
|
| Propranolol | 1 | 2013 | 102 | 0.110 |
Why?
|
| Disability Evaluation | 4 | 2017 | 298 | 0.110 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 55 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2019 | 181 | 0.100 |
Why?
|
| Thyroxine | 1 | 2012 | 62 | 0.100 |
Why?
|
| Brain | 2 | 2022 | 2176 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 235 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1615 | 0.100 |
Why?
|
| Hypertension | 1 | 2021 | 1533 | 0.100 |
Why?
|
| Rats, Long-Evans | 1 | 2012 | 203 | 0.100 |
Why?
|
| Quality of Life | 2 | 2022 | 1515 | 0.100 |
Why?
|
| Memory | 1 | 2013 | 214 | 0.100 |
Why?
|
| Critical Care | 1 | 2013 | 263 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2015 | 2356 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1074 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 113 | 0.090 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2010 | 20 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2019 | 2004 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2010 | 104 | 0.090 |
Why?
|
| Decision Making | 1 | 2014 | 410 | 0.090 |
Why?
|
| Life Change Events | 2 | 2009 | 223 | 0.090 |
Why?
|
| Smoking | 2 | 2009 | 1449 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2012 | 269 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 2011 | 172 | 0.090 |
Why?
|
| Lysophospholipids | 1 | 2011 | 209 | 0.090 |
Why?
|
| Mortality | 2 | 2021 | 162 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 96 | 0.080 |
Why?
|
| Sphingosine | 1 | 2011 | 315 | 0.080 |
Why?
|
| Sex Characteristics | 2 | 2008 | 295 | 0.080 |
Why?
|
| Heart Rate | 2 | 2008 | 568 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2014 | 1449 | 0.080 |
Why?
|
| Netherlands | 2 | 2019 | 68 | 0.080 |
Why?
|
| Cues | 1 | 2013 | 654 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 742 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2021 | 216 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 981 | 0.080 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2008 | 106 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2009 | 275 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2021 | 880 | 0.080 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2008 | 79 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 621 | 0.070 |
Why?
|
| Europe | 2 | 2017 | 196 | 0.070 |
Why?
|
| Child Abuse | 1 | 2009 | 186 | 0.070 |
Why?
|
| Canada | 2 | 2017 | 266 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2008 | 215 | 0.070 |
Why?
|
| Risk Factors | 3 | 2021 | 5720 | 0.070 |
Why?
|
| Australia | 2 | 2017 | 235 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2008 | 291 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 97 | 0.070 |
Why?
|
| Central Nervous System Depressants | 1 | 2007 | 182 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 221 | 0.060 |
Why?
|
| Age Factors | 3 | 2019 | 1860 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 567 | 0.060 |
Why?
|
| Rats | 1 | 2012 | 5300 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2020 | 7268 | 0.060 |
Why?
|
| Injections, Intra-Arterial | 2 | 2014 | 30 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1046 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2013 | 1341 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2014 | 215 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 24 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2022 | 99 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 824 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 46 | 0.050 |
Why?
|
| Progestins | 1 | 2021 | 19 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 110 | 0.050 |
Why?
|
| Ethanol | 1 | 2007 | 892 | 0.050 |
Why?
|
| Neuroglia | 1 | 2021 | 136 | 0.040 |
Why?
|
| Risk | 2 | 2013 | 563 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 386 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 329 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 43 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 1425 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 239 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 236 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 219 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 197 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 948 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2008 | 1506 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 142 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 105 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 2017 | 46 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1582 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 239 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2017 | 70 | 0.040 |
Why?
|
| Health Resources | 1 | 2017 | 76 | 0.040 |
Why?
|
| Cost Savings | 1 | 2017 | 110 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 442 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 84 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 977 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 711 | 0.030 |
Why?
|
| Phlebitis | 1 | 2014 | 4 | 0.030 |
Why?
|
| Neurons | 1 | 2021 | 881 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 74 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 503 | 0.030 |
Why?
|
| Stents | 1 | 2019 | 657 | 0.030 |
Why?
|
| Animals | 1 | 2012 | 20880 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 32 | 0.030 |
Why?
|
| Software | 1 | 2017 | 418 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2014 | 204 | 0.030 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 335 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2014 | 109 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 780 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 193 | 0.030 |
Why?
|
| Case Management | 1 | 2013 | 46 | 0.030 |
Why?
|
| Workflow | 1 | 2014 | 100 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 766 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 242 | 0.030 |
Why?
|
| Patient Safety | 1 | 2015 | 202 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 195 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2014 | 86 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 218 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 652 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 424 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2015 | 506 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2077 | 0.020 |
Why?
|
| Denmark | 1 | 2011 | 24 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2011 | 18 | 0.020 |
Why?
|
| Hypotension | 1 | 2011 | 74 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2014 | 320 | 0.020 |
Why?
|
| Troponin | 1 | 2010 | 25 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 120 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2011 | 131 | 0.020 |
Why?
|
| Diuretics | 1 | 2010 | 96 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 284 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 392 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 371 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 630 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2009 | 197 | 0.020 |
Why?
|
| Sphingolipids | 1 | 2011 | 337 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 384 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2008 | 150 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 2008 | 138 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2010 | 342 | 0.020 |
Why?
|
| Ceramides | 1 | 2011 | 578 | 0.020 |
Why?
|
| Child | 2 | 2009 | 6401 | 0.020 |
Why?
|
| Biotransformation | 1 | 2007 | 69 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2007 | 33 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2007 | 169 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 47 | 0.020 |
Why?
|
| Body Temperature | 1 | 2007 | 116 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 238 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 260 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 1265 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1753 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 1609 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 2265 | 0.010 |
Why?
|